Between others, ICBs targeting PD-1 and its ligand PD-L1 have been introduced to the treatment of the most aggressive subtype of triple-negative breast cancer (TNBC), corresponding mainly to the basal-like type of breast cancer in genomic TCGA studies [3,4]. The gene discussed is CD274; the disease is breast carcinoma.